CV Therapeutics wins European approval for brand name Ranexa Ranexa is approved for use in Europe as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.The product is...
Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improv - Clinical evidence for unique Ranexa(R) mechanism of action - PALO ALTO, Calif., Aug.19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
announced today that the Journal of Cardiovascular Electrophysiology has published a study of...
Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improv - Clinical evidence for unique Ranexa(R) mechanism of action - PALO ALTO, Calif., Aug.19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
announced today that the Journal of Cardiovascular Electrophysiology has published a study of...
CV Therapeutics wins European approval for brand name Ranexa CV Therapeutics has received approval from the European Medicines Agency for the brand name Ranexa.Ranexa is approved for use in Europe as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are...
CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) PALO ALTO, Calif., Aug.14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(R) (ranolazine).
On July 10, 2008, the Company...
CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) PALO ALTO, Calif., Aug.14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(R) (ranolazine).
On July 10, 2008, the Company...
CV Therapeutics Receives European Approval for the Brand Name Ranexa /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(R) (ranolazine).
On July 10, 2008, the Company announced that the EMEA had...
CV Therapeutics Receives European Approval for the Brand Name Ranexa(R) PALO ALTO, Calif., Aug.14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.
announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(R) (ranolazine).
On July 10, 2008, the Company...
CV Therapeutics Announces Ranexa Named Finalist for Prix Galien USA 2008 Award - Awards recognize innovative biopharmaceutical drugs and devices that have made a deep impact on the quality of human life - PALO ALTO, Calif., August 14, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.today announced that its...
The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, but I can't see it slowing down anytime soon.Some drugmakers' stock has been beaten down to respectable levels, and the falling dollar has made...
CV Therapeutics Reports 2008 Second Quarter Financial Results - Ranexa Revenue Grows 15 Percent Quarter-over-Quarter - PALO ALTO, Calif., July 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.today reported financial results for the second quarter ended June 30, 2008.
For the quarter ended...
CV Therapeutics Reports 2008 Second Quarter Financial Results PALO ALTO, Calif., July 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.today reported financial results for the second quarter ended June 30, 2008.
For the quarter ended June 30, 2008, the Company reported a net loss of $4.3 million,...
CV THERAPEUTICS INC EPS Estimated At -1.50: Current Recommendation is Neutral Company: CV THERAPEUTICS INC Report Headline: 'FDA Action Date For Ranexa Pending Applications Delayed Several Weeks' Report Date: July 28, 2008 Current FY EPS Estimate [FY2008]: -1.50 Previous EPS Estimate for Current FY [FY2008]: -1...
CVT Announces That FDA Continues to Review Ranexa(R) Applications In accordance with a special protocol assessment agreement between the FDA and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina...
CVT Announces That FDA Continues to Review Ranexa Applications _ CVT Announces That FDA Continues to Review Ranexa Applications.
CV angina drug action delayed by FDA Cardiovascular drug maker CV Therapeutics Inc.of Palo Alto said the Food and Drug Administration pushed its review of the angina drug Ranexa beyond Sunday.
That was the day the FDA was to give its approval or not for expanding the...
CVT Announces That FDA Continues to Review Ranexa Applications --FDA to provide draft labeling in the next few weeks-- PALO ALTO, Calif., July 28, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc.announced today that it has been informed by the U.S.
Food and Drug Administration (FDA) that it is...
CV angina drug action delayed by FDA That was the day the FDA was to give its approval or not for expanding the use of Ranexa as a frontline angina treatment, for use in heart arrhythmia patients and for a subset of diabetics with coronary heart disease.Ranexa ...
CV angina drug action delayed by FDA That was the day the FDA was to give its approval or not for expanding the use of Ranexa as a frontline angina treatment, for use in heart arrhythmia patients and for a subset of diabetics with coronary heart disease.Ranexa ...
CV Therapeutics said the FDA will take longer - than - expected to review angina drug application PALO ALTO, Calif.(AP) - Biotechnology company CV Therapeutics Inc.
said Monday the Food and Drug Administration will take longer than expected to review a request to approve its drug Ranexa as an initial treatment for angina.
